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A B S T R A C T
Zinc is necessary for growth and cells' division. Its deficiency may seriously affect antioxidant defense system and is
usually related to renal failure, gastrointestinal diseases and alcoholism. It is very important to know zinc status in dia-
lyzed patients and to prevent hypo- or hyperzincemia. Serum samples from 89 patients with chronic terminal renal failure
on regular hemodialysis were withdrawn for the estimation of zinc concentrations immediately before and after dialysis.
Serum zinc concentrations showed to be highly dependent on hemodialysis. In 57 (64%) patients, serum zinc concentra-
tions decreased, sometimes from very high to normal values. In remaining 32 (36%) patients serum zinc concentrations
tended to increase, but remained within normal range. Zinc supplementation may be recommended only in the patients
with proven zinc deficiency, but for all chronic renal failure patients it is questionable.
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Introduction
For human beings trace elements are essential nutri-
ents with many important functions. They are indispens-
able components of many enzymes, have some regulatory
functions and may affect immune reactions1,2. Zinc is co-
factor for many metal enzymes (>90%), including red
blood cells carboxyanhidrase, alkaline phosphatase and
enzymes involved in RNA and DNA synthesis (polymer-
ase). It is necessary for growth and cells' division. Espe-
cially fast-dividing cells in immune system (lymphocytes)
are sensitive to zinc deficiency. Zinc is found in red blood
cells in 75–88%. In the serum, zinc is completely bound
to proteins, 60–70% on albumin, the rest on alfa2-macro-
globulin and transferine. Serum concentrations are de-
pendent on daily variations, and abnormalities are related
to renal failure, gastrointestinal diseases and alcoholism.
The role of trace elements in hemodialysis (HD) pa-
tients has not yet been fully characterized. Abnormal-
ities of trace elements are primarily result of uremia3,4,
but they may be further modified by the dialysis pro-
cedure5. To prevent complications in chronic HD pa-
tients, it is very important to know and regulate the lev-
els of trace elements.
Zinc deficiency may be present in chronic renal fai-
lure6. It has been associatedwith anorexia, diarrhea, neg-
ative nitrogen balance, acrodermatitis, and impotency.
Reports indicate that dysgeusia and impotency may be
improved by giving zinc supplements to the patients.
Zinc deficiency seems to be correlated with some signs of
malnutrition in HD patients7. Moreover, a recent ran-
domized study in maintenance dialysis patients has shown
that the daily intake of a 2.2 mg zinc sulfate supplement
was able to correct serum zinc levels to normal values,
and this was associated with an increase in normalized
protein nitrogen appearance (nPNA)8. Recent studies
showed that zinc supplementation also correct the cho-
lesterol level which is often low and is the sign of the mal-
nutrition in HD patients9.
During HD, elimination of substances is dependent
upon concentration gradient between blood and dialysis
fluid, hydrophilic characteristics of the substance, bind-
ing to proteins, and molecular weight. Alterations of zinc
concentrations in serum of dialyzed patients have been
previously investigated3,10–12. The purpose of this study
was to assess the zinc serum concentrations in patients
with end-stage renal disease on maintenance HD.
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Materials and Methods
Eighty-nine HD patients were enrolled. Demographic
patient's characteristics and dialysis data are shown in ta-
ble 1. Blood samples were collected before and after HD
sessions.
Serum concentrations of electrolytes (sodium and po-
tassium) were routinely measured before and after HD
by phlame photometry on IL 943 (Instrumentation Labo-
ratory, USA). Additionally, we measured urea and crea-
tinine concentrations as well as concentrations of cal-
cium, phosphorus and glucose using conventional me-
thods on Hitachi 704 autoanalyzer (Roche, Germany).
Zinc determination is based on the fact that zinc
forms a red chelate complex with 2-(5-brom-2-pyridy-
lazo)-5-(N-propyl-N-sulfopropylamino)-phenol. The in-
crease of absorbance was measured on Opton spectro-
photometer and was proportional to the concentration of
total zinc13.
In all laboratory test determinations, commercial qu-
ality control samples were used as recommended.
Data were analyzed using the Sigma Plot Scientific
Graphing System, Version 6.10. Nonparametric test was
performed using Mann-Whitney U-test. The differences
were considered significant for p<0.05. Results are shown
as mean value ± standard deviation.
Results
Concentration changes of urea, creatinine, phospho-
rus, potassium and calcium in patients after HD were
significant, as expected (Table 2). In all patients concen-
trations of urea, creatinine, phosphorus and potassium
decreased for 50% or even more (p<0.001). HD influ-
enced calcium concentration increasing its values, in
some patients for up to 136% (p<0.001). Glucose and so-
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TABLE 1
DEMOGRAPHIC CHARACTERISTICS OF THE PATIENT’S
Characteristic Value (%)
Gender:
Male 41 (46%)
Female 48 (54%)
Mean patient’s age (years)* 63±11
Mean dialysis duration (years)* 4.98±3.39
Mean ultrafiltration rate in all treatments* 2.6±3.4
Type of dialysis membrane:
cellulose diacetate 44 (49%)
Polysulfone 45 (51%)
Type of dialysis:
low-flux procedure (hemodialysis) 66 (74%)
high-flux procedure (hemodiafiltration) 23 (26%)
mean dialysis delivered dose (Kt/V) * 1.21±0.15
Underlying renal disease:
diabetic nephropathy 25 (28%)
glomerulonephritis 22 (25%)
vascular disease 14 (16%)
pyelonephritis 9 (10%)
polycystic kidney disease 8 (9%)
interstitial nephritis 7 (8%)
other 4 (4%)
* X±SD
TABLE 2
SERUM CONCENTRATIONS OF ZINC, CALCIUM, PHOSPHORUS, SODIUM, POTASSIUM, UREA, CREATININE AND GLUCOSE BEFORE
AND AFTER HEMODIALYSIS (N=89)
Unit
Reference
range
Before hemodialysis
(X±SD)
After hemodialysis
(X±SD)
p
Zinc
mol/L 10.7–19.5 16.3±7.7 14.2±2.9 ns
Calcium mmol/L 2.0–2.6 2.3±0.3 2.9±0.2 <0.001
Phosphorus mmol/L 1.0–1.6 2.2±0.6 1.2±0.2 <0.001
Sodium mmol/L 133–147 138±4 138±3 ns
Potassium mmol/L 3.8–5.1 5.4±0.7 3.8±0.4 <0.001
Urea mmol/L to 7.5 26.8±7.4 8.4±3.6 <0.001
Creatinine
mol/L to 110 722±150 288±81 <0.001
Glucose mmol/L to 6.1 6.1±3.1 6.9±2.9 ns
Fig. 1. Serum zinc concentrations in patients before hemodialysis.
Percentage of patients with normal, elevated or low zinc concen-
trations.
dium concentrations did not change. Zinc concentrations
showed to be dependent on HD. Before HD, 50 patients
(56%) had normal, 15 (17%) low, and 24 (27%) elevated
serum zinc concentrations (Figure 1). In 57 (64%) pa-
tients zinc decreased from higher values (up to 42 mol/L)
to the final one that remained within normal range (up
to 10.7 mol/L). In remained 32 (36%) patients, zinc con-
centrations increased (up to 19.5 mol/ L), but remained
within normal range (Figures 2, 3). We compared zinc
values and nutritional parameters in HD patients (Table
3).
Discussion
It is well known that patients on chronic HD are at
high risk of developing trace element imbalances11,14,
which can further induce different abnormalities in this
patients15–17. Such abnormalities of zinc metabolism and
alterations in serum zinc concentrations have been re-
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Fig. 2. Alterations in serum zinc concentrations before and after hemodialysis (HD).
Fig. 3. Changes in zinc concentration after hemodialysis depending
on elevated, low or normal concentration before hemodialysis (HD).
X – axis represents the groups of patients according to serum zinc
concentrations and total patients sample.
TABLE 3
COMPARISON OF ZINC VALUES AND NUTRITIONAL PARAMETERS IN HAEMODIALYSIS PATIENTS (X±SD)
Nutritional parameter
Zinc
<11.5 mol/L
(N=19)
11.5-18.5 mol/L
(N=43)
>18.5 mol/L
(N=27)
p*
Body Mass Index 24±4 24±4 24±5 ns
Serum albumin (g/L) 38±6 39±5 38±5 ns
C-reactive protein 9.3±6 8.7±5 9.7±5 ns
Cholesterol (mmol/L) 5.5±1.9 5.5±1.9 5.1±17 ns
Serum creatinine (mol/L) 886±120 792±202 833±177 ns
Protein catabolic rate 0.55±0.05 0.55±0.05 0.57±0.07 ns
*Mann-Whitney U test
ported10,12. Most of authors reported low zinc concentra-
tions in serum of patients undergoing HD. Lee at al.18
have found that 78% of patients on HD had low plasma
zinc concentrations and Castro at al.19 reported that
about 20% of such patients were hypozincemic. Krachler
et al.11 found that plasma concentrations of zinc continu-
ously increase during HD, but always stay at or below the
reference range. Low plasma zinc concentrations tending
to increase with HD duration were found by Skarupski-
ene et al.5. Striking was the report of Prehn3 that serum
zinc level increases after treatment using the hemo-
dialysis membrane KN 401. He also reported benefit of
HD on zinc status in these patients. He found that serum
level of zinc is reduced with the progression of chronic re-
nal failure, but also pointed out that in advanced renal
failure hypozincemia is more pronounced with conserva-
tive therapy than in the patients on regular HD.
Our results strongly suggest that serum concentra-
tions of zinc are normalized after the HD treatment. In
the present study, serum samples from 89 patients with
end-stage renal failure treated by regular HD were with-
drawn for the estimation of zinc concentrations immedi-
ately before and after dialysis. Before HD 24 patients
(27%) had elevated and 15 patients (17%) had low serum
zinc concentrations, regarding the reference range for
adult healthy persons (Figure 1). After HD all the results
of serum zinc concentrations were within reference ran-
ge (Figure 2).
Further, we found no correlations between zinc val-
ues and nutritional parameters in HD patients (Table 3).
There are many factors that can influence serum zinc
concentrations. Bogden et al.19 reported that certain dis-
posable dialytic coils are contaminated with zinc and re-
lease substantial quantities of zinc during HD, producing
high post-dialysis plasma concentrations. Low plasma
zinc level was more often found in patients with <12
hour/week of HD duration and <12 months of HD treat-
ment (5). At the same time, Castro et al.20 concluded that
the occurrence of hypozincemia was not related to dialy-
sis modality and that zincemia did not reflect low dietary
intake of zinc. Still, efficiency of HD and water treatment
may play an important role, because increased zinc level
in serum after HD can be the consequence of reducing to-
tal blood volume in these patients. It was shown that ex-
cept for aluminum, blood levels of trace metals in HD pa-
tients were not related to their medication18, but that
environmental factors, diet, and the aging process may
contribute to the trace metal burden in uremia. Even in
the case of zinc supplementation, plasma zinc levels were
not changed, according to findings of Richard et al.21.
Alterations of serum zinc during HD are still unclear
and are probably affected by individual patient's metabo-
lism and specific illness. Future studies have to address
more specific parameters, e.g. alterations in serum pro-
teins, enzymes and antioxidants, specific conditions like
osteoporosis, as well as patient's age, duration of HD and
medication. In the meantime, although serum concentra-
tion of zinc do not reflect the real body status of this
trace element, it can be easily determined in routine
practice and may give a quick insight and warning about
possible disorders of zinc metabolism.
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KONCENTRACIJA CINKA U SERUMU U BOLESNIKA NA REDOVITOJ HEMODIJALIZI
S A @ E T A K
Cink je neophodan element za rast stanica, njegov manjak mo`e bitno utjecati na antioksidativni obrambeni sustav,
obi~no u svezi sa kroni~nom bolesti bubrega, bolestima probavnog trakta i kroni~nim alkoholizmom. U bolesnika na
dijalizi zna~ajno je znati koncentraciju cinka, te sprije~iti hipo i hipercinkemiju. Analizirali smo 89 uzoraka krvi bo-
lesnika sa terminalnim zatajenjem bubrega na redovitoj hemodijalizi. Odre|ene su koncentracije cinka prije i poslije
postupka hemodijalize. Rezultati su pokazali da su koncentracije cinka bile ovisne o postupku hemodijalize. U 57 (64%)
bolesnika, koncentracija cinka u serumu sni`ena je postupkom hemodijalize, ponekad od vrlo visokih do normalnih
vrijednosti. U preostalih 32 (36%) bolesnika, koncentracija cinka je porasla nakon postupka hemodijalize, ali su vri-
jednosti ostale u normalnim granicama. Suplementi cinka su preporu~ljivi samo u bolesnika sa dokazanom deficijen-
cijom cinka, ali u je upitna njihova primjena u svih bolesnika sa kroni~nim bubre`nim zatajenjem.
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